GPR183 (extracellular) Blocking Peptide (#BLP-GR063) is the original antigen used for immunization during Anti-GPR183 (extracellular) Antibody (#AGR-063) generation. The blocking peptide binds and ‘blocks’ Anti-GPR183 (extracellular) primary antibody, this makes it a good negative reagent control to help confirm antibody specificity in western blot and immunohistochemistry applications. This control is also often called a pre-adsorption control.
- Western blot analysis of rat brain membranes (lanes 1 and 4), mouse brain lysates (lanes 2 and 5) and rat lung membranes (lanes 3 and 6):
- Western blot analysis of rat spleen membranes (lanes 1 and 3) and mouse spleen membranes (lanes 2 and 4):
- Western blot analysis of human Daudi B-lymphoblast cell line lysates (lanes 1 and 3) and human Jurkat T-cell leukemia cell line lysates (lanes 2 and 4):
- Expression of GPR183 in in rat parietal cortex.Immunohistochemical staining of perfusion-fixed frozen mouse brain sections with Anti-GPR183 (extracellular) Antibody (#AGR-063), (1:1200), followed by donkey anti-rabbit-biotin and streptavidin-Cy3. A. GPR183 immunoreactivity (red) appears in soma and apical dendrite profiles (arrows). B. Pre-incubation of the antibody with GPR183 (extracellular) Blocking Peptide (BLP-GR063), suppressed staining. Cell nuclei are stained with DAPI (blue).
- Peptide (C)GND(S)DLYAHHSTAR, corresponding to amino acid residues 18 - 31 of human GPR183 (Accession P32249).